DDInter1607 DDInter973
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
Ritonavir {u} (Compound) binds {v} (Gene) ABCC1
ABCC1 {u} (Gene) is bound by {v} (Compound) Irinotecan
Ritonavir {u} (Compound) causes {v} (Side Effect) Visual impairment
Visual impairment {u} (Side Effect) is caused by {v} (Compound) Irinotecan
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Irinotecan
Ritonavir {u} (Compound) binds {v} (Gene) ABCC1
ABCC1 {u} (Gene) is upregulated by {v} (Disease) colon cancer
colon cancer {u} (Disease) is treated by {v} (Compound) Irinotecan
Ritonavir {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Irinotecan
Ritonavir {u} (Compound) binds {v} (Gene) CYP3A7
CYP3A7 {u} (Gene) is bound by {v} (Compound) Norfloxacin
Norfloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Irinotecan
Ritonavir {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Citalopram
Citalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Irinotecan
Ritonavir {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) regulates {v} (Gene) RRP8
RRP8 {u} (Gene) is upregulated by {v} (Compound) Irinotecan
Ritonavir {u} (Compound) binds {v} (Gene) SLCO1B1
SLCO1B1 {u} (Gene) is associated with {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Irinotecan
Ritonavir {u} (Compound) causes {v} (Side Effect) Visual impairment
Visual impairment {u} (Side Effect) is caused by {v} (Compound) Citalopram
Citalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Irinotecan
Ritonavir (Compound) binds ABCC1 (Gene) and ABCC1 (Gene) is bound by Irinotecan (Compound)
Ritonavir (Compound) causes Visual impairment (Side Effect) and Visual impairment (Side Effect) is caused by Irinotecan (Compound)
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may lead to a major life threatening interaction when taken with Irinotecan
Ritonavir (Compound) binds ABCC1 (Gene) and ABCC1 (Gene) is upregulated by colon cancer (Disease) and colon cancer (Disease) is treated by Irinotecan (Compound)
Ritonavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan
Ritonavir (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Norfloxacin (Compound) and Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Irinotecan
Ritonavir (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Citalopram (Compound) and Citalopram may cause a minor interaction that can limit clinical effects when taken with Irinotecan
Ritonavir (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) regulates RRP8 (Gene) and RRP8 (Gene) is upregulated by Irinotecan (Compound)
Ritonavir (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) is associated with breast cancer (Disease) and breast cancer (Disease) is treated by Irinotecan (Compound)
Ritonavir (Compound) causes Visual impairment (Side Effect) and Visual impairment (Side Effect) is caused by Citalopram (Compound) and Citalopram may cause a minor interaction that can limit clinical effects when taken with Irinotecan